Ahsan Rao1, Amna Suliman1, Giles Story2, Sabine Vuik2, Paul Aylin3, Ara Darzi1. 1. Department of Surgery and Cancer, Faculty of Medicine, St Mary's Hospital, Imperial College London, London, UK. 2. Centre for Health Policy, Institute for Global Health Innovation, St Mary's Hospital, Imperial College London, London, UK. 3. School of Public Health, Faculty of Medicine, Dr Foster Unit, London, UK.
Abstract
BACKGROUND: Second-generation antipsychotics (SGAs) are often prescribed in the treatment of Behavioral and Psychological Symptoms of Dementia (BPSD), however, their use has been discouraged in light of clinical trials suggesting that they cause an increased risk of cerebrovascular accidents (CVAs). OBJECTIVE: Aim of the study was to assess relative risk of CVA in dementia patients prescribed SGA rather than first-generation antipsychotics (FGAs), through meta-analysis of population-based studies. METHODS: A literature search was conducted using several relevant databases. Five studies were included in the review and data were pooled to conduct meta-analysis using the inverse variance method. RESULTS: A total of 79,910 patients were treated with SGAs and 1287 cases of CVA were reported. Of 48,135 patients treated with FGAs, a total of 511 cases of CVA were reported. The relative risk of CVA was 1.02 (95% CI 0.56-1.84) for the SGA group. There was no significant difference in the risk of stroke (p = 0.96) between groups, but significant heterogeneity was found among the results of included studies (p < 0.001). CONCLUSION: Meta-analysis of population-based data suggested that the use of SGAs as opposed to FGAs to control BPSD is not associated with significantly increased risk of CVA.
BACKGROUND: Second-generation antipsychotics (SGAs) are often prescribed in the treatment of Behavioral and Psychological Symptoms of Dementia (BPSD), however, their use has been discouraged in light of clinical trials suggesting that they cause an increased risk of cerebrovascular accidents (CVAs). OBJECTIVE: Aim of the study was to assess relative risk of CVA in dementiapatients prescribed SGA rather than first-generation antipsychotics (FGAs), through meta-analysis of population-based studies. METHODS: A literature search was conducted using several relevant databases. Five studies were included in the review and data were pooled to conduct meta-analysis using the inverse variance method. RESULTS: A total of 79,910 patients were treated with SGAs and 1287 cases of CVA were reported. Of 48,135 patients treated with FGAs, a total of 511 cases of CVA were reported. The relative risk of CVA was 1.02 (95% CI 0.56-1.84) for the SGA group. There was no significant difference in the risk of stroke (p = 0.96) between groups, but significant heterogeneity was found among the results of included studies (p < 0.001). CONCLUSION: Meta-analysis of population-based data suggested that the use of SGAs as opposed to FGAs to control BPSD is not associated with significantly increased risk of CVA.
Authors: Leonor Laredo; Emilio Vargas; Antonio Javier Blasco; Maria Dolores Aguilar; Alfonso Moreno; Antonio Portolés Journal: J Am Geriatr Soc Date: 2011-06-30 Impact factor: 5.562
Authors: Philip S Wang; Sebastian Schneeweiss; Jerry Avorn; Michael A Fischer; Helen Mogun; Daniel H Solomon; M Alan Brookhart Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245
Authors: Hannah Wunsch; Derek C Angus; David A Harrison; Olivier Collange; Robert Fowler; Eric A J Hoste; Nicolette F de Keizer; Alexander Kersten; Walter T Linde-Zwirble; Alberto Sandiumenge; Kathryn M Rowan Journal: Crit Care Med Date: 2008-10 Impact factor: 7.598
Authors: Hanneke C Beerens; Caroline Sutcliffe; Anna Renom-Guiteras; Maria E Soto; Riitta Suhonen; Adela Zabalegui; Christina Bökberg; Kai Saks; Jan P H Hamers Journal: J Am Med Dir Assoc Date: 2013-11-09 Impact factor: 4.669
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18
Authors: K S Frederiksen; C Cooper; G B Frisoni; L Frölich; J Georges; M G Kramberger; C Nilsson; P Passmore; L Mantoan Ritter; D Religa; R Schmidt; E Stefanova; A Verdelho; M Vandenbulcke; B Winblad; G Waldemar Journal: Eur J Neurol Date: 2020-07-26 Impact factor: 6.089